US · ACRS · BIOTECHNOLOGY
Aclaris Therapeutics, Inc. (ACRS) intrinsic value and stock valuation
$3.44as of 2026-11-21 · Mkt cap 888.26M
Data updated · price as of 2026-11-21
- P/E
- Pro
- P/B
- Pro
- P/S
- Pro
Price history
Price charts, the InvestorsCraft value line, and the fair-value band are Pro features.
Aclaris Therapeutics, Inc. DCF and intrinsic value
InvestorsCraft values ACRS with the Chepakovich two-stage DCF model — currently rated strongly undervalued. How the model works · Run your own DCF prefilled from ACRS’s statements →
Aclaris Therapeutics, Inc. Graham Number
The Graham Number is not defined for negative earnings or book value. Guide · Calculator →
How the business is doing
Fiscal 2013–2025, USD
Is it expensive?
Each multiple against its own 15-year range, or against peers where no history is available
Peers
Same-industry companies, ranked by market cap
Peer comparison
The peer comparison table is shown only to users with a Pro subscription.
Financials
Statements by fiscal year
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.83M | $18.7M | $31.3M | $29.8M | $6.76M |
| Operating income | -$-76.38M | -$-141.93M | -$-97.36M | -$-89.85M | -$-89.72M |
| Net income | -$-64.92M | -$-132.06M | -$-88.48M | -$-86.91M | -$-90.86M |
| EPSd | -$-529.27K | -$-1.71M | -$-1.27M | -$-1.33M | -$-1.6M |
| Operating cash flow | -$-47.11M | -$-20.07M | -$-78.33M | -$-67.57M | -$-52.13M |
| Capital expenditure | -$-110K | -$-120K | -$-1.31M | -$-600K | -$-310K |
| Free cash flow | -$-47.11M | -$-20.2M | -$-79.63M | -$-68.17M | -$-52.44M |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M |
| Total debt | $2.12M | $0.00 | $430K | $680K | $690K |
| Net debt | -$-17.84M | -$-24.57M | -$-39.45M | -$-44.59M | -$-26.66M |
| Total equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M |
| Cash and short-term investments | $90.8M | $113.6M | $119.1M | $217.6M | $191.4M |
Income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Revenue | $7.83M | $18.7M | $31.3M | $29.8M | $6.76M |
| Cost of revenue | $2.09M | $2.79M | $18.1M | $12M | $4.71M |
| Gross profit | $5.74M | $15.9M | $13.2M | $17.8M | $2.05M |
| Research and development expenses | $52.7M | $33.6M | $98.4M | $77.8M | $43.8M |
| Selling, general and administrative expenses | $22M | $22.2M | $31.1M | $25.1M | $23.6M |
| Other expenses | $7.49M | $102.1M | -$-18.96M | $4.7M | $24.3M |
| Operating expenses | $82.1M | $157.9M | $110.5M | $107.7M | $91.8M |
| Cost and expenses | $84.2M | $160.7M | $128.6M | $119.6M | $96.5M |
| Interest income | $7.64M | $7.95M | $0.00 | $0.00 | $0.00 |
| Interest expense | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Depreciation and amortization | $450K | $810K | $860K | $800K | $920K |
| Ebitda | -$-64.47M | -$-51.72M | -$-115.45M | -$-84.36M | -$-64.46M |
| Operating income | -$-76.38M | -$-141.93M | -$-97.36M | -$-89.85M | -$-89.72M |
| Total other income/expenses, net | $11.5M | $9.87M | $8.51M | $2.95M | -$-1.14M |
| Income before tax | -$-64.92M | -$-132.06M | -$-88.85M | -$-86.91M | -$-90.86M |
| Income tax expense | $0.00 | $0.00 | -$-370K | $0.00 | $0.00 |
| Net income | -$-64.92M | -$-132.06M | -$-88.48M | -$-86.91M | -$-90.86M |
| Weighted average shares outstanding | $122.7M | $77.3M | $69.8M | $65.2M | $56.7M |
| Weighted average diluted shares outstanding | $122.7M | $77.3M | $69.8M | $65.2M | $56.7M |
Balance sheet
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Cash and short-term investments | $90.8M | $113.6M | $119.1M | $217.6M | $191.4M |
| Net receivables | $5.57M | $320K | $300K | $480K | $620K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total current assets | $151.4M | $126M | $128.9M | $231.6M | $205M |
| Property, plant and equipment, net | $0.00 | $1.01M | $1.62M | $1.1M | $1.33M |
| Goodwill and intangible assets | $0.00 | $0.00 | $270K | $6.97M | $7.05M |
| Long-term investments | $60.6M | $90.3M | $62.8M | $12.2M | $34.2M |
| Total non-current assets | $9.1M | $94.4M | $68.6M | $23.1M | $46.2M |
| Total assets | $160.5M | $220.3M | $197.4M | $254.6M | $251.2M |
| Accounts payable | $13.2M | $4.69M | $8.88M | $10.4M | $9.98M |
| Short-term debt | $550K | $0.00 | $430K | $680K | $690K |
| Deferred revenue | $3.94M | $3.89M | $0.00 | $0.00 | $0.00 |
| Total current liabilities | $28.6M | $31.6M | $31M | $21.9M | $22.9M |
| Long-term debt | $1.56M | $0.00 | $0.00 | $0.00 | $0.00 |
| Deferred revenue, non-current | $16.2M | $20M | $0.00 | $0.00 | $0.00 |
| Total non-current liabilities | $28.7M | $33.2M | $9.27M | $35M | $30.9M |
| Capital lease obligations | $1.56M | $0.00 | $430K | $680K | $690K |
| Total liabilities | $57.4M | $64.8M | $40.2M | $57M | $53.9M |
| Common stock | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Retained earnings | -$-967.78M | -$-902.86M | -$-770.8M | -$-682.32M | -$-595.41M |
| Accumulated other comprehensive income (loss) | $610K | $100K | -$-110K | -$-900K | -$-220K |
| Total equity | $103.1M | $155.6M | $157.2M | $197.6M | $197.3M |
| Total investments | $131.4M | $179.3M | $142M | $184.5M | $198.3M |
| Total debt | $2.12M | $0.00 | $430K | $680K | $690K |
| Net debt | -$-17.84M | -$-24.57M | -$-39.45M | -$-44.59M | -$-26.66M |
Cash flow statement
| 2025 | 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|---|
| Net income | -$-64.92M | -$-132.06M | -$-88.48M | -$-86.91M | -$-90.86M |
| Depreciation and amortization | $450K | $810K | $860K | $800K | $920K |
| Stock-based compensation | $12.4M | $10.9M | $20.5M | $15M | $14.1M |
| Change in working capital | $2.67M | $10.9M | $9.39M | -$-1.2M | -$-1.34M |
| Accounts receivable | $6.14M | -$-20K | $190K | $140K | $150K |
| Inventory | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Accounts payable | $8.45M | -$-4.19M | -$-1.47M | $370K | $3.65M |
| Net cash provided by operating activities | -$-47.11M | -$-20.07M | -$-78.33M | -$-67.57M | -$-52.13M |
| Investments in property, plant and equipment | -$-110K | -$-120K | -$-1.31M | -$-600K | -$-310K |
| Acquisitions, net | $0.00 | $0.00 | $0.00 | -$-13.23M | $167.3M |
| Net cash used for investing activities | $48.4M | -$-69.77M | $46.2M | $12.6M | -$-167.63M |
| Common stock issued | $0.00 | $74.9M | $26.7M | $72.7M | $238.2M |
| Common stock repurchased | -$-450K | $0.00 | $0.00 | $0.00 | $0.00 |
| Dividends paid | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Net cash used for financing activities | -$-5.86M | $74.5M | $26.7M | $72.9M | $225.1M |
| Net change in cash | -$-4.61M | -$-15.31M | -$-5.4M | $17.9M | $5.29M |
| Cash at end of period | $20M | $24.6M | $39.9M | $45.3M | $27.4M |
| Operating cash flow | -$-47.11M | -$-20.07M | -$-78.33M | -$-67.57M | -$-52.13M |
| Capital expenditure | -$-110K | -$-120K | -$-1.31M | -$-600K | -$-310K |
| Free cash flow | -$-47.11M | -$-20.2M | -$-79.63M | -$-68.17M | -$-52.44M |
Line items
Line items
Line items
About Aclaris Therapeutics, Inc.
Aclaris Therapeutics, Inc., a biopharmaceutical firm operating in the United States, is currently in the clinical development phase, focused on creating novel therapeutic agents for various immune-inflammatory conditions. The company's operations are divided into two primary divisions: the Therapeutics segment, dedicated to discovering and progressing innovative treatments to address crucial unmet needs in immuno-inflammatory disorders; and the Contract Research segment, which delivers specialized laboratory services. The company's pipeline features several investigational compounds. Among these is Zunsemetinib, an MK2 inhibitor, being developed to treat moderate to severe cases of rheumatoid arthritis, psoriatic arthritis, and hidradenitis suppurativa. Another significant candidate is ATI-1777, a soft JAK 1/3 inhibitor, intended for the management of moderate to severe atopic dermatitis. Additionally, Aclaris is advancing ATI-2138, an ITK/TXK/JAK3 inhibitor, as a potential intervention for T cell-mediated autoimmune diseases; a Gut-Biased Program targeting inflammatory bowel disease; and ATI-2231, an MK2 inhibitor, for the treatment of pancreatic and metastatic breast cancer. Established in 2012, Aclaris Therapeutics, Inc. has its corporate headquarters situated in Wayne, Pennsylvania.
- CEO
- Neal S. Walker
- Employees
- 73
- Beta
- 0.77
Explore
Frequently asked questions
What is the intrinsic value of Aclaris Therapeutics, Inc. (ACRS)?
Aclaris Therapeutics, Inc. (ACRS) is currently strongly undervalued based on the InvestorsCraft IC model — IC value is more than 50% above the price. The exact intrinsic value is available to Pro subscribers. How the IC value is calculated.
Is ACRS undervalued?
ACRS trades at a price of $3.44 (Nov 21, 2026): strongly undervalued — IC value is more than 50% above the price.
How is the intrinsic value calculated?
InvestorsCraft estimates intrinsic value with four methods: the Chepakovich valuation model (IC), an AI-assisted estimate, the Graham-Dodd formula, and the Graham Formula. How the IC value is calculated.
How often is this page updated?
Prices are refreshed each trading day; valuation inputs update when new financial statements are processed. This page was last updated Nov 21, 2026.
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Figures marked d are derived from the figures shown — for example upside = IC ÷ price − 1, CAGR over the last five fiscal years, and range bounds are 15-year or peer minimum and maximum.